Uptrend Under Pressure 100
Institutional selling is building — 7 distribution days in the last 25 sessions. Severe risk · 100/100 · 7 distribution days (SPY) Oct 26 Full briefing →
View
Simple research view

WST · West Pharmaceutical Services, Inc.

$394.73 +0.66% Oct 26 close
Detected setup Pocket Pivot · Setup Score 70/100

Stand aside — setup invalidated

Setup score 70, but distribution days reach 5 or more — stand aside until the condition resets.

2 independent risk warnings also present. Review before relying on the bullish setup.

Ask about WST

Switch to Advanced for indicator panels, raw grades, provenance, drawing tools, and full technical tables.

$WST

West Pharmaceutical Services, Inc.

West Pharmaceutical Services, Inc. is a large-cap Medical Specialties company in the Health Technology sector with a market cap of $28B.

Health Technology Medical Specialties stock Stage 2 · Advancing Base 1
$394.73 latest close
Market Structure
Trend structure: downtrend
Latest event: structure_shift (bullish)
Support 358.67–360.29 · 3 touches · moderate
Join to Watchlist $WST Share card
Verdict · setup score 70/100 · data Oct 26 close · latest session

Stand aside — setup invalidated

Setup score 70, but distribution days reach 5 or more — stand aside until the condition resets.

Review six verdicts Inspect chart
Recent price action · daily
$350$375$400AugSepOct$395

What would change this verdict

What needs to turn for this to become buyable — the top failing checks across the legend council:

  • Minervini 2. Quarterly EPS growth ≥ 25% — +4.4% QoQ
  • Minervini 2. Revenue growth ≥ 20% YoY — +6.2% YoY
  • O'Neil C: Quarterly EPS acceleration ≥ 25% — +4.4% QoQ
  • O'Neil M: Market in confirmed uptrend — Market phase: uptrend_under_pressure
  • Weinstein Volume expansion above average — Volume ratio 1.21x
  • Weinstein Weekly price coiling (Stage 2 consolidation) — Tightening weekly range confirms base
Minority view — the council disagrees here
  • Minervini: watch Trend-template read: 10/13 pass; wait for the soft misses to improve.
  • O'Neil: avoid CANSLIM read: fails C: Quarterly EPS acceleration ≥ 25%.
  • Weinstein: watch Stage-analysis read: Stage 2 is present; 2 supporting checks need improvement.
73 Strong
Legend Score · rates the stock Strong (73/100) — held back by eps growth

Our proprietary 0-100 rating — the answer to Wall Street's black-box scores. Five pillars, each computed from real scan data, each explained below in plain English.

  • Relative Strength (25%) 92
  • Trend Template (25%) 100
  • Institutional Footprint (20%) 70
  • EPS Growth (15%) 30
  • Quality (SMR-like) (15%) 44

RS rank 91: top 9% of all stocks — true leadership. Trend template 8/8: price above rising 50/150/200-day lines — textbook uptrend structure. Institutional score 70: mild accumulation. EPS up +0% — growing, but below the 25% leadership bar. Quality 44: weak fundamentals (sales growth 30, return on equity 41, leverage 100). Updated 2026-10-27.

Earnings

Pre-earnings setup

Next earnings Thursday, October 29, 2026 Before market open Exact clock time not supplied by source

Deterministic evidence

WST+0.66%
Sector proxy · XLV+0.00%
Broad market · SPY+0.71%
Same completed session window ending 2026-10-26. WST was +0.66 points vs XLV. -0.05 points vs SPY.
CatalystPending Stock reactionPositive Sector reactionWeak Opening surgePending Event riskEarnings-driven

Session internals Strong momentum

Rule: closed up, at or above the open, in the top third of the day's range. Judged on internals, not on the size of the move.

Vs prior close+0.66% From the open+1.26% Range position92% GapNo gap
QQQ confirmationConfirming (+1.11%) SMH confirmationConfirming (+2.74%)
Short-term conviction -1 points.
  • A sourced earnings report is still pending inside the risk window; ordinary technical conviction is reduced until it is out.
Price bars, sourced event fields, and benchmark math only. This can adjust displayed short-term conviction; it does not change the stored scanner score or readiness.

Ask a Legend to interpret this evidence → Commentary only — never scanner evidence or a sizing recommendation.

Price $394.73 +0.7% Oct 26 close
52W High $397.15 0.6% below high
Wks Since High 0w
Base Depth 2.3%
RS Rank 80 percentile of scan
SMA 50 $362.97
Avg Vol 539,103
Rel Vol (Oct 26) 1.21× 1.88× on up days
More stats
52W Low $223.83
Tight Wks 0
Base B1
SMA 200 $310.70
RS Line vs High -0.1%
RS Line Slope +4.6% ▲
Group Rank #21/66
ADR% 2.2%
ATR(14) $7.98 (2.0%)
Vol Pace (live) N/A
A/D Days 21A / 8D
A/D Rating A+
VDU Bars 0/10 d
Power Trend 12d
Earnings in 2d
Position in 52-week range 99thpercentile of the 52-week range
$223.83low
$397.15high

WST Chart

Interactive price, volume, RS, RSI, and MACD charts are available after sign in.

Create a free account to load the full interactive chart for WST.

Create Free Account

Technical Analysis Report Card

$WST · $394.73 · as of 2026-10-26 · multi-factor read
100
/ 100
Technicals 100/100
Reference read from price & volume only — the verdict at the top of the page decides the action.

Trend · Daily / Weekly / Monthly

Daily ▲ Uptrend
Weekly ▲ Uptrend
Monthly ▲ Uptrend

Moving Averages

50-day$362.97 ↑
100-day$354.03 ↑
200-day$310.70 ↑
Bullish (50 > 200)

RSI (14)

Reading70.5 · Overbought

Overbought — buyers extended; watch for a pause or pullback.

MACD (12/26/9)

StateBullish
Histogram+1.524

Bullish — MACD above its signal line and above zero. Histogram contracting.

Bollinger Bands (20,2)

%B / Width89% · 11.6%

Near the upper band — buyers in control.

Volume · Buyer vs Seller

Up/Down vol1.88 · Accumulation
Rel volume1.21×
Pocket pivots · 10d4
5d vs 50d vol121%
Heavy vol up / down0 / 0

Accumulation — volume is concentrated on up days; buyers dominate. Recent volume is easing versus its baseline.

  • Pocket pivot 2 sessions ago — up-day volume beat every down day of the prior 10 sessions.

Support & Resistance

R · $397.1552-week high
Price · $394.73now
S · $359.49swing level
S · $349.41swing level
S · $343.48swing level

Fibonacci · Uptrend swing

23.6%$373.25
38.2%$358.47
50.0%$346.52
61.8%$334.58
78.6%$317.57

Retracement support zones measured from the recent swing low up to the high.

The verdict is free. The trade plan is Pro.
Unlock the exact entry, stop-loss, profit target, and reward-to-risk for WST — plus the full 500+ symbol scanner and Ask-the-Legends chat.
Start your 7-day free trial →
Daily uptrendWeekly uptrendMonthly uptrendAbove 200-day MA50/200 bullishRSI overbought
Want this read in a legend's voice? Ask a Legend about WST
Generic technical analysis generated mechanically from price & volume — educational research only, not financial advice or a personalized recommendation. Levels are illustrative; confirm on your own chart. New to these terms? →
Legend Verdicts 6 methodology checks

Who would consider this setup, why it qualifies, and what blocks it — calculated from the same deterministic methodology rules used across Legend AI.
How to read the numbers: the setup score (70/100, in the verdict band) rates this trade setup. Each legend's A–D grade rates the same setup against that legend's own checklist — so a high score next to a C grade is not a contradiction. The setup can be strong without fitting that legend's style. When the council disagrees, the verdict band breaks the tie.

Council consensus: 7 of 9 legends are Watching — building, not yet a confirmed buy.
Minervini Watch B Trend-template read: 10/13 pass; wait for the soft misses to improve.

partialEnter on break of $394.73 pivot with stop at $375.09 (risk 5.0%). SEPA Grade B (5/7).

Passing evidence
1.1 Price > 150-day MA AND 200-day MAPrice $394.73, MA150 $332.21, MA200 $310.70
1.2 150-day MA > 200-day MAMA150 $332.21 vs MA200 $310.70
Failing evidence
2. Quarterly EPS growth ≥ 25%+4.4% QoQ
2. Revenue growth ≥ 20% YoY+6.2% YoY
10/13 checks
Method → Playbook → Ask →
O'Neil Avoid D CANSLIM read: fails C: Quarterly EPS acceleration ≥ 25%.

partialRule check says AVOID (4/8 checks passed) — CANSLIM read: fails C: Quarterly EPS acceleration ≥ 25%.

Passing evidence
L: RS rank ≥ 80 (IBD leadership)RS rank 91
A: Annual earnings & revenue qualityRev +6.2% | ROE 17.9%
Failing evidence
C: Quarterly EPS acceleration ≥ 25%+4.4% QoQ
M: Market in confirmed uptrendMarket phase: uptrend_under_pressure
4/8 checks
Method → Playbook → Ask →
Weinstein Watch C Stage-analysis read: Stage 2 is present; 2 supporting checks need improvement.

mediumClassic Stage 2 advancing phase — strong weekly trend confirms uptrend. This is Weinstein's sweet spot: buy and hold while price remains above the 30-week MA.

Passing evidence
Stage 2 (Advancing phase) confirmedStage 2 (Advancing)
Price above 30-week MA (200-day proxy)Price $394.73 vs MA200 $310.70
Failing evidence
Volume expansion above averageVolume ratio 1.21x
Weekly price coiling (Stage 2 consolidation)Tightening weekly range confirms base
5/7 checks
Method → Playbook → Ask →
dennis Watch B Turtle read: no breakout yet. Price is pressing the 20-day high. The system waits for the print; it never anticipates.
Passing evidence
No breakdown below the 20-day channel20-day low $359.49
Volatility-unit sizing (1N ≈ 1% of equity)1N = $8.30 (2.10% of price); the Turtles size 1 unit so a 1N move ≈ 1% of equity, making the 2N stop ≈ 2% equity risk
Failing evidence
S1: 20-day Donchian breakoutNot confirmed
S2: 55-day Donchian breakoutNot confirmed
6/8 checks
Method → Playbook → Ask →
zanger Avoid C Zanger read: a hard gate is broken — either the pattern is not one of his six, or the entry is more than 5% past the breakout. He would not touch this.
Passing evidence
Not extended (≤5% above the breakout point)Measured as passing
Partial-profit plan: sell 20-30% at +15-20%Scale 20-30% at $453.94-$473.68; trail the rest
Failing evidence
Named Zanger pattern onlyPocket Pivot is not one of Zanger's six
Breakout volume 1.5-2.0x averageNot confirmed
4/6 checks
Method → Playbook → Ask →
zweig Watch D Zweig read: part of his screen passes but not all: EPS growth above the market (≥15% QoQ); Reasonable price for the growth (P/E ≤ 35); Insider buying — wait for the full growth screen before treating this as a Zweig setup.
Passing evidence
Price strength (RS ≥ 70)RS score 91 — Zweig buys strength, not bargains
Breadth momentum: 10-day A/D ratio10-day A/D 1.17 (2025 adv / 1725 dec) — participation expanding
Failing evidence
EPS growth above the market (≥15% QoQ)+4.4% QoQ — Zweig wants growth above the S&P average
Reasonable price for the growth (P/E ≤ 35)Trailing P/E 58.1x — no PEG or forward P/E stored
3/8 checks
Method → Playbook → Ask →
Livermore Watch B Pivotal-point read: constructive evidence is present, but volume vs average is unresolved.
Passing evidence
Price$394.73
Relative strengthRS 91
Failing evidence
Volume vs average1.21x
Pivotal point cleared on expanding volumeNot confirmed
4/6 checks
Method → Playbook → Ask →
Darvas Watch B Box-theory read: constructive evidence is present, but volume vs average is unresolved.

mediumStock is at the top of its box — Darvas would wait for a decisive breakout on volume.

Passing evidence
Price$394.73
Relative strengthRS 91
Failing evidence
Volume vs average1.21x
Box top broken on heavy volumeNot confirmed
4/6 checks
Method → Playbook → Ask →
Wyckoff Watch B Supply-and-demand read: constructive evidence is present, but volume vs average is unresolved.
Passing evidence
Price$394.73
Relative strengthRS 91
Failing evidence
Volume vs average1.21x
Sign of Strength confirmed on expanding volumePrice hasn't cleared the pivot yet — confirmation pending
4/6 checks
Method → Playbook → Ask →
Base & Breakout
Breakout follow-through

No active breakout tracked — Legend AI monitors daily for pivot-point breaks. What's a breakout?

Unlock Base & Breakout Tracking
RS Line vs SPY 52-week relative strength · blue = RS line · dashed = MA50 · dot = NH NH
123RS Line (52W)
Accumulation / Distribution last 65 sessions · green = acc on high vol · red = dist on high vol Net +11 A+
A: 21 D: 10 Net: +1165 sessions
Minervini · Grade Card
Fundamentals & leadership quality — Minervini’s published criteria · 5/7 met
B 5/7 criteria
Separate score from the Minervini Trend Template (8/8): the Trend Template grades the price structure, this grades the company & leadership (earnings, sales, margins, RS rank). A stock can ride a clean trend while its fundamentals lag, so the two often differ by design — they are not the same checklist.
✗ EPS acceleration ≥25% QoQ +4%
✗ Revenue growth ≥20% YoY +6%
✓ Gross margin ≥30% 36%
✓ ROE ≥17% 18%
✓ RS rating ≥80 (leadership) 91
✓ Stage 2 uptrend (Weinstein) Stage 2
✓ Within 25% of 52W high -0.6%

Method Playbook

Trade it like Zweig EXACT LEVELS · PRO
Zweig D · Watch — The deterministic methodology check is Watch; wait for the failing or incomplete criteria to improve before the trigger can qualify.
Pivot
Pro level
Published-method rule: Use the stock's recent consolidation high — Zweig buys strength in screened growers, not breakdowns.
Evidence: Canonical setup geometry is available with Pro.
Entry trigger
Pro level
Published-method rule: Buy only when the growth screen passes: EPS growth above the market, PEG ≤ 1.5 (reasonable for the growth), insider buying, and RS leadership.
Evidence: Canonical setup geometry is available with Pro.
Initial stop
Pro level
Published-method rule: Define the loss before entry — Zweig's risk rule. Sell when the growth story breaks: earnings decelerate or the valuation stretches past reason.
Evidence: Canonical setup geometry is available with Pro.
Trail
Rule-based
Published-method rule: Hold winners as long as earnings keep growing and the price holds its trend; sell half on a climax run.
Evidence: Planned management rule; no stored stop or broker order is changed automatically.
Exit / invalidation
Pro level
Published-method rule: Exit when EPS growth falls below the market, the PEG stretches past reason, insiders stop buying — or the Super Model flips the market to defensive.
Evidence: Canonical setup geometry is available with Pro.
Deterministic educational plan, not a recommendation. No order or stop is changed automatically. Method and sources →

Pattern Analysis

Pocket Pivot ⚠ 3rd-stage base ⚠ Rising wedge
70 setup score
RS Score 91
Trend template 8/8 ✓
CANSLIM 72.4* (B)
volume ratio: 1.47 near moving avg: ✓ upper close: ✓ shooting star: ✗ price past buy range: ✗ vol beats down: ✓ bars since signal: 2 signal close: 394.03 validation reason: valid pocket-pivot multi tf evaluated: ✓ multi tf reason: weekly trend template 8/8 confirmed + no fresh 13-week low
Why This Setup? D+W Confluence
Pocket Pivot · schematic

Up vol 679,936 vs max down vol 462,541 (near MA), upper_close=yes, bars_ago=2 | Strong trend (8/8) | Top RS (91) | Moderate pattern (65%) | Accumulation (1.9× up/dn vol) | RS at new high | Power Trend | Stage 2 | Readiness 65/100 (watch) | CANSLIM 72.4 (B) | ⚠ 3rd-stage base; Rising wedge

Ask a Legend ▾
The Universal Edge Check · context only

What the setup still has going for it, recorded for later. The verdict above stands — these principles do not overrule it.

4/7 universals met
  • Clear of earnings — not met in 2 days — event risk
  • Not chasing (in range) — partly met Pivot distance unknown
  • Volume confirms — partly met 1.2× average — light
  • A relative-strength leader — met RS rank 80
  • Asymmetric reward — met Met — levels are a Pro detail
  • In a confirmed uptrend — met Stage 2 · Trend template 8/8
  • Risk is defined — met Met — levels are a Pro detail
Why these seven? → The Universal Edge

Minervini Trend Template

8/8 ✓

Grades the price structure — moving-average stacking, distance from the 52-week high/low, and relative strength above the ≥70 uptrend bar. This is the technical trend check; the company's fundamentals and ≥80 RS leadership are scored separately in the Grade Card.

Price above SMA 150 & 200 $394.73 vs SMA150 $332.21 / SMA200 $310.70
SMA 150 above SMA 200 SMA150 $332.21 vs SMA200 $310.70
SMA 200 trending up Slope +10.37 over 20 days
SMA 50 above SMA 150 & 200 SMA50 $362.97
Price above SMA 50 $394.73 vs SMA50 $362.97
30%+ above 52-week low +76.4% from $223.83
Within 25% of 52-week high -0.6% from $397.15
RS score above 70 RS 91

Fundamentals

52W Range
99%
Mkt Cap SEC
27.8B
EPS QoQ
+4%
Rev YoY
+6%
ROE
18%
Gross Margin
36%
D/E
0.07
EPS TTM
$6.79
P/E TTM
58.1x
Float
70M
Insider
No Buy

Company

Company profile
West Pharmaceutical Services, Inc.
WST · NYSE · Health Technology · Medical Specialties
Track all markets on TradingView
O'Neil · Grade Card
CANSLIM — current EPS, annual EPS, new highs, supply, leader RS, inst. sponsorship, market
B 72.4* CANSLIM * disqualified on C, M
C · Curr. EPS
62
A · Annual EPS
71
N · New Highs
100
S · Supply/Demand
100
L · Leader RS
91
I · Inst. Spons.
50
M · Market
30

Weekly Context

Multi-timeframe signals from weekly bars
W. Trend
8/8
W. RS
95
W. Support
$290.41
W. Resist
$397.15
W. Patterns
Base Breakout
Weekly Structure

Scan History

20× streak
Oct 23: 70 (Pocket Pivot)Oct 26: 70 (Pocket Pivot)Oct 27: 70 (Pocket Pivot)70
Oct 27
Pocket Pivot ✓ Gate
70
Oct 26
Pocket Pivot ✓ Gate
70 0.0%
Oct 23
Pocket Pivot ✓ Gate
70 +0.7%

Latest News

Headlines for WST
Loading headlines…

Get the full picture on WST

Pro members see entry/stop/target levels, R:R ratios, intraday alerts, and every setup detected across 500+ symbols daily.

Start 7-Day Free Trial